article thumbnail

The role of physiology in the contemporary management of coronary artery disease

Heart BMJ

Coronary physiology assessment, including epicardial and microvascular investigations, is a fundamental tool in the contemporary management of patients with coronary artery disease. Coronary revascularisation guided by functional evaluation has demonstrated superiority over angiography-only-guided treatment.

article thumbnail

Randomised trial of stable chest pain investigation: 3-year clinical and quality of life results from CE-MARC 2

Open Heart

We aimed to determine whether different strategies to manage suspected stable angina affected medium-term cardiovascular event rates and patient-reported quality of life (QoL) measures.

article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Stent 105
article thumbnail

A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina

Frontiers in Cardiovascular Medicine

Background Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD). Methods Two different economic evaluation models were developed as part of the analysis.

Angina 64
article thumbnail

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Frontiers in Cardiovascular Medicine

The prevention and treatment of cardiogenic dementia are essential to improve the quality of life, particularly in the elderly and aging population. This study describes the changes in cognitive function associated with coronary artery disease, myocardial infarction, heart failure, atrial fibrillation and heart valve disease.

article thumbnail

Clinical development and proof of principle testing of new regenerative vascular endothelial growth factor-D therapy for refractory angina: rationale and design of the phase 2 ReGenHeart trial

Open Heart

Background Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional treatment options.

Angina 52
article thumbnail

Is Anemia Common After Heart Bypass Surgery?

MIBHS

Heart bypass surgery, or coronary artery bypass graft surgery (CABG), is performed to treat patients with severe coronary artery disease (CAD). By taking steps to manage anemia, patients can ensure a more successful recovery and improved quality of life after surgery. What is Heart Bypass Surgery?